Cargando…
SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population
Vaccines are the solution to overcome SARS-CoV-2. This study aimed to determine the post-Sinopharm vaccine safety-profile and immunity through antibody titers. Data were collected using a structured questionnaire from Egyptian participants who received two doses of Sinopharm vaccine. Data were divid...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779046/ https://www.ncbi.nlm.nih.gov/pubmed/35062679 http://dx.doi.org/10.3390/vaccines10010018 |
_version_ | 1784637475106324480 |
---|---|
author | Elgendy, Marwa O. El-Gendy, Ahmed O. Alzarea, Abdulaziz Ibrahim Mahmoud, Sarah Alqahtani, Saad S. Fahmy, Alzhraa M. El-Seedi, Hesham R. Sayed, Ahmed M. Alatawi, Ahmed D. Abdelrahim, Mohamed E. A. Alanazi, Abdullah S. |
author_facet | Elgendy, Marwa O. El-Gendy, Ahmed O. Alzarea, Abdulaziz Ibrahim Mahmoud, Sarah Alqahtani, Saad S. Fahmy, Alzhraa M. El-Seedi, Hesham R. Sayed, Ahmed M. Alatawi, Ahmed D. Abdelrahim, Mohamed E. A. Alanazi, Abdullah S. |
author_sort | Elgendy, Marwa O. |
collection | PubMed |
description | Vaccines are the solution to overcome SARS-CoV-2. This study aimed to determine the post-Sinopharm vaccine safety-profile and immunity through antibody titers. Data were collected using a structured questionnaire from Egyptian participants who received two doses of Sinopharm vaccine. Data were divided into three parts, the first and second parts were to detect participants’ post-first and second dose symptoms and practices, and the third for the results of IgG anti spike protein antibodies test and laboratory tests. Pain, redness, swelling at the injection site, headache, fatigue, and lethargy were the most common post-vaccine symptoms for both first and second doses. Most of the participants felt mild or no symptoms after vaccination. The symptoms started mostly during the first day post-vaccination and lasted for no more than two days. Forty-nine percent of the participants resulted in positive antibodies tests on day 18 post-vaccination. The average antibody level for vaccinated participants with past SARS-CoV-2 infection was much higher than that for non-past infected participants. These vaccines’ administration methods need to be reevaluated by changing the dose, dose interval, adding a third dose, or mixing it with other vaccines with different techniques to improve their protection rates. Further studies are required to validate this finding. |
format | Online Article Text |
id | pubmed-8779046 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87790462022-01-22 SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population Elgendy, Marwa O. El-Gendy, Ahmed O. Alzarea, Abdulaziz Ibrahim Mahmoud, Sarah Alqahtani, Saad S. Fahmy, Alzhraa M. El-Seedi, Hesham R. Sayed, Ahmed M. Alatawi, Ahmed D. Abdelrahim, Mohamed E. A. Alanazi, Abdullah S. Vaccines (Basel) Article Vaccines are the solution to overcome SARS-CoV-2. This study aimed to determine the post-Sinopharm vaccine safety-profile and immunity through antibody titers. Data were collected using a structured questionnaire from Egyptian participants who received two doses of Sinopharm vaccine. Data were divided into three parts, the first and second parts were to detect participants’ post-first and second dose symptoms and practices, and the third for the results of IgG anti spike protein antibodies test and laboratory tests. Pain, redness, swelling at the injection site, headache, fatigue, and lethargy were the most common post-vaccine symptoms for both first and second doses. Most of the participants felt mild or no symptoms after vaccination. The symptoms started mostly during the first day post-vaccination and lasted for no more than two days. Forty-nine percent of the participants resulted in positive antibodies tests on day 18 post-vaccination. The average antibody level for vaccinated participants with past SARS-CoV-2 infection was much higher than that for non-past infected participants. These vaccines’ administration methods need to be reevaluated by changing the dose, dose interval, adding a third dose, or mixing it with other vaccines with different techniques to improve their protection rates. Further studies are required to validate this finding. MDPI 2021-12-24 /pmc/articles/PMC8779046/ /pubmed/35062679 http://dx.doi.org/10.3390/vaccines10010018 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Elgendy, Marwa O. El-Gendy, Ahmed O. Alzarea, Abdulaziz Ibrahim Mahmoud, Sarah Alqahtani, Saad S. Fahmy, Alzhraa M. El-Seedi, Hesham R. Sayed, Ahmed M. Alatawi, Ahmed D. Abdelrahim, Mohamed E. A. Alanazi, Abdullah S. SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population |
title | SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population |
title_full | SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population |
title_fullStr | SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population |
title_full_unstemmed | SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population |
title_short | SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population |
title_sort | sars-cov-2 post vaccinated adverse effects and efficacy in the egyptian population |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779046/ https://www.ncbi.nlm.nih.gov/pubmed/35062679 http://dx.doi.org/10.3390/vaccines10010018 |
work_keys_str_mv | AT elgendymarwao sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT elgendyahmedo sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT alzareaabdulazizibrahim sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT mahmoudsarah sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT alqahtanisaads sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT fahmyalzhraam sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT elseediheshamr sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT sayedahmedm sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT alatawiahmedd sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT abdelrahimmohamedea sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation AT alanaziabdullahs sarscov2postvaccinatedadverseeffectsandefficacyintheegyptianpopulation |